Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients

Abstract

B-cell activating factor belonging to tumour necrosis factor family (BAFF) is essential for B-cell survival and function through interaction with its receptors BAFF receptor 3 (BR3), B-cell maturation antigen (BCMA) and/or transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), though BCMA and/or TACI can also bind to a proliferation-inducing ligand (APRIL). We evaluate the correlation of the expressions of these ligands/receptors with different clinical manifestations of systemic lupus erythematosus (SLE). Levels of BAFF and APRIL in plasma from 73 SLE patients were determined by enzyme-linked immunosorbent assay. Expressions of BR3, TACI and BCMA on CD19+ B cells were detected by flow cytometry. Clinical data were collected and disease activity was evaluated using SLEDAI-2000. SLE patients had elevated BAFF and APRIL levels in their plasma. BAFF levels correlated positively with SLEDAI while negatively with the BR3 protein expression on CD19+ B cells (p < .05). The detected BR3 protein expression in SLE patients was reduced on CD19+IgD+CD27—, CD19+IgD+CD27+ as well as CD19+IgD—CD27+ B cells compared to the counterparts of healthy controls (p < .001), whereas SLE patients did not differ from healthy controls in BR3 mRNA levels. In untreated new-onset patients, the expression rate of BR3 on CD19+ B cells correlated negatively with SLEDAI (p < .05). Elevation of BAFF and reduction of BR3 on CD19+ B cells were more obvious in those with lupus nephritis (LN, p < .05). TACI expression on CD19+ B cells was up-regulated only in those subjects with LN (p < .05). Elevated plasma BAFF and reduced BR3 protein expression on peripheral B cells could act as biomarkers for active disease in SLE patients. High expression of TACI may indicate the occurrence of LN.

Keywords

BAFF BAFF receptors systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Schneider P. , MacKay F. , Steiner V. , et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-1756.

Moore PA , Belvedere O. , Orr A. , et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.

Tribouley C. , Wallroth M. , Chan V. , et al. Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem 1999; 380: 1443-1447.

Mukhopadhyay A. , Ni J. , Zhai Y. , et al. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274: 15978-15981.

Shu HB , Hu WH , Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens . J Leukoc Biol 1999; 65: 680-683.

Scapini P. , Nardelli B. , Nadali G. , et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297-302.

Craxton A. , Magaletti D. , Ryan EJ , et al. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003; 101: 4464-4471.

Nardelli B. , Belvedere O. , Roschke V. , et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.

Hahne M. , Kataoka T. , Schroter M. , et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188: 1185-1190.

10.

Yu G. , Boone T. , Delaney J. , et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000; 1: 252-256.

11.

Marsters SA , Yan M. , Pitti RM , et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-788.

12.

Ng LG , Sutherland AP , Newton R. , et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173: 807-817.

13.

Thompson JS , Bixler SA , Qian F. , et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-2111.

14.

Gross JA , Johnston J. , Mudri S. , et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.

15.

Mackay F. , Woodcock SA , Lawton P. , et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-1710.

16.

Khare SD , Sarosi I. , Xia XZ , et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 2000; 97: 3370-3375.

17.

Cheema GS , Roschke V. , Hilbert DM , et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-1319.

18.

Szodoray P. , Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren’s syndrome. Scand J Immunol 2005; 62: 421-428.

19.

Seyler TM , Park YW , Takemura S. , et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-3092.

20.

Zhang J. , Roschke V. , Baker KP , et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.

21.

Mariette X. , Roux S. , Zhang J. , et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis 2003; 62: 168-171.

22.

Koyama T. , Tsukamoto H. , Miyagi Y. , et al. Raised serum APRIL levels in patients with systemic lupus erythematosus . Ann Rheum Dis 2005; 64: 1065-1067.

23.

Avery DT , Kalled SL , Ellyard JI , et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003 ; 112: 286-297.

24.

Gras MP , Laabi Y. , Linares-Cruz G. , et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol 1995 ; 7: 1093-1106.

25.

Stohl W. BlySfuLNess does not equal blissfuLNess in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun 2005; 8: 289-304.

26.

Vugmeyster Y. , Seshasayee D. , Chang W. , et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol 2006; 168: 476-489.

27.

Stohl W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases . Endocr Metab Immune Disord Drug Targets 2006; 6: 351-358.

28.

Furie RA , Petri MA , Wallace DJ , et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 1143-1151.

29.

Linker-Israeli M. , Deans RJ , Wallace DJ , et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147: 117-123.

30.

Lin Z. , Dan-Rong Y. , Xiao-Qing T. , et al. Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients. J Clin Lab Anal 2007; 21: 183-187.

31.

Becker-Merok A. , Nikolaisen C. , Nossent HC B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006; 15: 570-576.

32.

Stohl W. , Metyas S. , Tan SM , et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486.

33.

Ju S. , Zhang D. , Wang Y. , et al. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006; 39: 1131-1137.

34.

Sellam J. , Miceli-Richard C. , Gottenberg JE , et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren’s syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 790-797.

35.

Roschke V. , Sosnovtseva S. , Ward CD , et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-4321.

36.

Gavin AL , Ait-Azzouzene D. , Ware CF , et al. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003; 278: 38220-8228.

37.

Le Pottier L. , Bendaoud B. , Renaudineau Y. , et al. New ELISA for B cell-activating factor . Clin Chem 2009; 55: 1843-1851.

38.

Stohl W. , Metyas S. , Tan SM , et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus . Ann Rheum Dis 2004; 63: 1096-1103.

39.

Carter RH , Zhao H. , Liu X. , et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3943-3954.

40.

Seshasayee D. , Valdez P. , Yan M. , et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18: 279-288.

41.

Ramanujam M. , Wang X. , Huang W. , et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173: 3524-3534.

42.

Schiemann B. , Gommerman JL , Vora K. , et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-2114.

43.

Yang M. , Hase H. , Legarda-Addison D. , et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol 2005; 175: 2814-2824.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB